These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24900329)

  • 61. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.
    Skerlj RT; Bridger GJ; Kaller A; McEachern EJ; Crawford JB; Zhou Y; Atsma B; Langille J; Nan S; Veale D; Wilson T; Harwig C; Hatse S; Princen K; De Clercq E; Schols D
    J Med Chem; 2010 Apr; 53(8):3376-88. PubMed ID: 20297846
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
    Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
    J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High level expression, activation, and antagonism of CC chemokine receptors CCR2 and CCR3 in Chinese hamster ovary cells.
    Parody TR; Stone MJ
    Cytokine; 2004 Jul; 27(1):38-46. PubMed ID: 15207250
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Unusual chemokine receptor antagonism involving a mitogen-activated protein kinase pathway.
    Ogilvie P; Thelen S; Moepps B; Gierschik P; da Silva Campos AC; Baggiolini M; Thelen M
    J Immunol; 2004 Jun; 172(11):6715-22. PubMed ID: 15153488
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543.
    Showell HJ; Conklyn MJ; Alpert R; Hingorani GP; Wright KF; Smith MA; Stam E; Salter ED; Scampoli DN; Meltzer S; Reiter LA; Koch K; Piscopio AD; Cortina SR; Lopez-Anaya A; Pettipher ER; Milici AJ; Griffiths RJ
    J Pharmacol Exp Ther; 1998 Jun; 285(3):946-54. PubMed ID: 9618393
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
    Nakazato A; Sakagami K; Yasuhara A; Ohta H; Yoshikawa R; Itoh M; Nakamura M; Chaki S
    J Med Chem; 2004 Aug; 47(18):4570-87. PubMed ID: 15317467
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes.
    Sayyed SG; Ryu M; Kulkarni OP; Schmid H; Lichtnekert J; Grüner S; Green L; Mattei P; Hartmann G; Anders HJ
    Kidney Int; 2011 Jul; 80(1):68-78. PubMed ID: 21508925
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Alpha-aminothiazole-gamma-aminobutanoic amides as potent, small molecule CCR2 receptor antagonists.
    Zhou C; Guo L; Parsons WH; Mills SG; MacCoss M; Vicario PP; Zweerink H; Cascieri MA; Springer MS; Yang L
    Bioorg Med Chem Lett; 2007 Jan; 17(2):309-14. PubMed ID: 17092717
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists.
    Zheng Y; Qin L; Zacarías NV; de Vries H; Han GW; Gustavsson M; Dabros M; Zhao C; Cherney RJ; Carter P; Stamos D; Abagyan R; Cherezov V; Stevens RC; IJzerman AP; Heitman LH; Tebben A; Kufareva I; Handel TM
    Nature; 2016 Dec; 540(7633):458-461. PubMed ID: 27926736
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity.
    Brown GD; Shi Q; Delucca GV; Batt DG; Galella MA; Cvijic ME; Liu RQ; Qiu F; Zhao Q; Barrish JC; Carter PH
    Bioorg Med Chem Lett; 2016 Jan; 26(2):662-666. PubMed ID: 26631321
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2.
    O'Boyle G; Brain JG; Kirby JA; Ali S
    Mol Immunol; 2007 Mar; 44(8):1944-53. PubMed ID: 17081610
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria.
    Potluri V; Shandil RK; Gavara R; Sambasivam G; Campo B; Wittlin S; Narayanan S
    Malar J; 2020 Oct; 19(1):365. PubMed ID: 33046062
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery of a novel CCR3 selective antagonist.
    Naya A; Kobayashi K; Ishikawa M; Ohwaki K; Saeki T; Noguchi K; Ohtake N
    Bioorg Med Chem Lett; 2001 May; 11(9):1219-23. PubMed ID: 11354381
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.
    Cai C; Kang FA; Hou C; O'Neill JC; Opas E; McKenney S; Johnson D; Sui Z
    Bioorg Med Chem Lett; 2013 Jan; 23(1):351-4. PubMed ID: 23182090
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines.
    Dugar S; Hollinger FP; Mahajan D; Sen S; Kuila B; Arora R; Pawar Y; Shinde V; Rahinj M; Kapoor KK; Bhumkar R; Rai S; Kulkarni R
    ACS Med Chem Lett; 2015 Dec; 6(12):1190-4. PubMed ID: 26713102
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.
    Gillman KW; Starrett JE; Parker MF; Xie K; Bronson JJ; Marcin LR; McElhone KE; Bergstrom CP; Mate RA; Williams R; Meredith JE; Burton CR; Barten DM; Toyn JH; Roberts SB; Lentz KA; Houston JG; Zaczek R; Albright CF; Decicco CP; Macor JE; Olson RE
    ACS Med Chem Lett; 2010 Jun; 1(3):120-4. PubMed ID: 24900185
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
    Zhang Y; Wu X; Xue X; Li C; Wang J; Wang R; Zhang C; Wang C; Shi Y; Zou L; Li Q; Huang Z; Hao X; Loomes K; Wu D; Chen HW; Xu J; Xu Y
    J Med Chem; 2019 May; 62(9):4716-4730. PubMed ID: 30964293
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis.
    Lebre MC; Vergunst CE; Choi IY; Aarrass S; Oliveira AS; Wyant T; Horuk R; Reedquist KA; Tak PP
    PLoS One; 2011; 6(7):e21772. PubMed ID: 21747955
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.
    Williams PD; Anderson PS; Ball RG; Bock MG; Carroll L; Chiu SH; Clineschmidt BV; Culberson JC; Erb JM; Evans BE
    J Med Chem; 1994 Mar; 37(5):565-71. PubMed ID: 8126695
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Optimisation of a novel series of potent and orally bioavailable azanaphthyridine SYK inhibitors.
    Garton NS; Barker MD; Davis RP; Douault C; Hooper-Greenhill E; Jones E; Lewis HD; Liddle J; Lugo D; McCleary S; Preston AGS; Ramirez-Molina C; Neu M; Shipley TJ; Somers DO; Watson RJ; Wilson DM
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4606-4612. PubMed ID: 27578246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.